Roche Holdings AG Basel (OTCMKTS:RHHBY) Downgraded by ValuEngine
RHHBY has been the subject of a number of other reports. Deutsche Bank raised shares of Roche Holdings AG Basel from a hold rating to a buy rating in a research note on Thursday, June 20th. Liberum Capital lowered shares of Roche Holdings AG Basel from a buy rating to a hold rating in a research note on Thursday, June 20th. UBS Group raised shares of Roche Holdings AG Basel from a neutral rating to a buy rating in a research note on Friday, July 26th. Finally, Zacks Investment Research raised shares of Roche Holdings AG Basel from a hold rating to a buy rating and set a $37.00 price target for the company in a research note on Tuesday, July 9th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. Roche Holdings AG Basel has a consensus rating of Hold and a consensus target price of $37.00.
Shares of OTCMKTS:RHHBY opened at $33.91 on Tuesday. The company has a 50 day moving average of $34.33 and a 200-day moving average of $33.98. The firm has a market cap of $232.23 billion, a P/E ratio of 14.62, a P/E/G ratio of 2.22 and a beta of 0.48. Roche Holdings AG Basel has a twelve month low of $28.74 and a twelve month high of $35.90. The company has a current ratio of 1.40, a quick ratio of 1.11 and a debt-to-equity ratio of 0.53.
Roche Holdings AG Basel Company Profile
Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.
Featured Article: Why are analyst ratings important in trading stocks?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.